Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.54 |
| ▸ | PPARG | P37231 | 7/20 | 0.54 |
| ▸ | PPARD | Q03181 | 7/20 | 0.54 |
| ▸ | PPARA | Q07869 | 7/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575619 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL2345376 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL336842 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL1333784 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL4285232 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL2483372 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL22612557 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL22612553 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL22612525 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG | |
| SCHEMBL346960 | 1.00 | FFAR4 (0.57) | FFAR4FFAR1ALDH1A1GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 712 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260079166-A1 | METHODS FOR DETECTING FRACTURE-RELATED INFECTION (FRI) | UNIV INDIANA TRUSTEES (US) | 2026-03-19 | — | — | US | claimed |
| EP-4667511-A2 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | Tiba Biotech LLC (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250354174-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | TIBA BIOTECH LLC (US) | 2025-11-20 | — | — | US | claimed |
| US-12410448-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TIBA BIOTECH LLC (US) | 2025-09-09 | — | — | US | claimed |
| US-20240384308-A1 | METHODS FOR THE BIOTECHNOLOGICAL PRODUCTION OF ALDEHYDE MIXTURES | SYMRISE AG (DE) | 2024-11-21 | — | — | US | claimed |
| CN-118562914-A | A Ganoderma fermentation product containing selenium-enriched Ganoderma triterpene and polysaccharide for repairing liver injury, and its fermentation method | 中科药创(青岛)发酵工程有限公司 | 2024-08-30 | — | — | CN | claimed |
| EP-4396362-A1 | METHODS FOR THE BIOTECHNOLOGICAL PRODUCTION OF ALDEHYDE MIXTURES | Symrise AG (DE) | 2024-07-10 | — | — | EP | claimed |
| EP-4387607-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | Tiba Biotech LLC (US) | 2024-06-26 | — | — | EP | claimed |
| CN-118056015-A | Biotechnological production method of aldehyde mixture | 西姆莱斯有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-117915958-A | Dendritic structures as non-viral vectors in gene delivery | 蒂巴生物技术有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-2120586-A2 | ADJUVANTS AND METHODS OF USING THEM | Archer-Daniels-Midland Company (US) | 2009-11-25 | — | — | EP | claimed |
| CN-100522183-C | Earthworm acidic-part medicine for treating cough asthma disease and preparing method | UNIV SHANGHAI JIAOTONG (CN) | 2009-08-05 | — | — | CN | claimed |
| WO-2008100896-A2 | ADJUVANTS AND METHODS OF USING THEM | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2008-08-21 | — | — | WO | claimed |
| US-20080194410-A1 | acidificers propionic acid, methyl acetic acid, acetic acid, lactic acid, fumaric acid, citric acid, phosphoric acid mixed with lecithin emulsifier; nonphenolic nonionic surfactant such as ethoxylated monolycerides, fatty acid ethoxylates, polyoxyethylene alkyl ethers, polyoxyethylene alkyl esters; water | ARCHER DANIELS MIDLAND COMPANY | 2008-08-14 | — | — | US | claimed |
| CN-1850118-A | Earthworm acidic-part medicine for treating cough asthma disease and preparing method | UNIV SHANGHAI JIAOTONG (CN) | 2006-10-25 | — | — | CN | claimed |
| CN-1658860-A | Method of inhibiting angiogenesis | QUEEN ELIZABETH HOSPITAL RES F (AU) | 2005-08-24 | — | — | CN | claimed |
| US-20050143463-A1 | Method of inhibiting angiogenesis | THE QUEEN ELIZABETH HOSPITAL RESEARCH FOUNDATION INC. (AU) | 2005-06-30 | — | — | US | claimed |
| EP-1531804-A1 | METHOD OF INHIBITING ANGIOGENESIS | The Queen Elizabeth Hospital Research Foundation Inc., (AU) | 2005-05-25 | — | — | EP | claimed |
| WO-2003092671-A1 | METHOD OF INHIBITING ANGIOGENESIS | THE QUEEN ELIZABETH HOSPITAL RESEARCH FOUNDATION INC. (AU) | 2003-11-13 | — | — | WO | claimed |
| WO-2003092672-A1 | METHOD OF INHIBITING REJECTION OF TRANSPLANTED MATERIAL | THE QUEEN ELIZABETH HOSPITAL RESEARCH FOUNDATION INC. (AU) | 2003-11-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250354174-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | TLR9, TLR3, TSG101 | FFAR4 2817/4885FFAR1 1706/4885ALDH1A1 3422/4885 |
| US-20050143463-A1 | Method of inhibiting angiogenesis | FASN, VEGFA, FLT4 | FFAR4 51/4885FFAR1 45/4885ALDH1A1 709/4885 |
| US-12410448-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TLR9, TLR3, TSG101 | FFAR4 2817/4885FFAR1 1706/4885ALDH1A1 3422/4885 |
| US-20260079166-A1 | METHODS FOR DETECTING FRACTURE-RELATED INFECTION (FRI) | FGF23, FGB, SFRP1 | FFAR4 2932/4885FFAR1 3155/4885ALDH1A1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.